Endogenous accumulation of IFN-γ in IFN-γ-R-/- mice increases resistance to B16F10-Nex2 murine melanoma: A model for direct IFN-γ anti-tumor cytotoxicity in vitro and in vivo

Cytokines, Cellular and Molecular Therapy

Volumn 7, Issue 3, 2002, Pages 107-116

  Rodrigues, Elaine G ^a   Travassos, Luiz R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

IFN R mice; Interferon gamma; Murine melanoma; Tumor cytotoxicity; Tumor resistance

Indexed keywords

CD3 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER RESISTANCE; CARCINOGENESIS; CELL ACTIVATION; CELL ASSAY; CELL LINE; CYTOTOXICITY; DISEASE MODEL; DISEASE PREDISPOSITION; DOSE CALCULATION; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MELANOMA B16; MOUSE; MOUSE STRAIN; NONHUMAN; PERITONEUM MACROPHAGE; PHYSICAL SENSITIVITY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DETERMINATION; PROVOCATION TEST; SPLEEN CELL; SUPERNATANT; TIME; TOXICITY; TUMOR GROWTH; TUMOR RESISTANCE; WILD TYPE;

ANIMALS; DNA-BINDING PROTEINS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON REGULATORY FACTOR-1; INTERFERON TYPE II; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MELANOMA, EXPERIMENTAL; MICE; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; PHOSPHOPROTEINS; RECEPTORS, INTERFERON; SPLEEN; TUMOR CELLS, CULTURED;

EID: 0037478836     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: 10.1080/13684730310000121     Document Type: Article

References (41)

1. Fidler IJ, Selection of successive tumor lines for metastasis. Nat New Biol (1973) 242: 148-9.
2. Overwijk WW, Tsung A, Irvine KR et al, gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 188: 277-86.
3. Bowne WB, Srinivasan R, Wolchok JD et al, Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 190: 1717-22.
4. Xu X, Azumi N, Skelton HG et al, Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen. Eur J Cancer (1996) 32A: 168-73.
5. Naftzger C, Takechi Y, Kohda H et al, Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA (1996) 93: 14809-14.
6. Weber LW, Bowne WB, Wolchok JD et al, Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 102: 1258-64.
7. Hawkins WG, Gold JS, Blachere NE et al, Xenogeneic DNA immunization in melanoma models for minimal residual disease. J Surg Res (2002) 102: 137-43.
8. Lollini PL, Colombo MP, De Giovanni C et al, In vivo reexpression of H-2 antigens in B 16 melanoma cells. Exp Clin Immunogenet (1985) 2: 14-23.
9. Bohm W, Thoma S, Leithauser F et al, T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J Immunol (1998) 161: 897-908.
10. Boehm U, Klamp T, Groot M, Howard JC, Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 15: 749-95.
11. Billiau A, Heremans H, Vermeire K, Matthys P, Immunomodulatory properties ofinterferon-gamma. An update. Ann N Y Acad Sci (1998) 856: 22-32.
12. Hawley RG, Berger LC, Growth control mechanisms in multiple myeloma. Leuk Lymph (1998) 29: 465-75.
13. Detjen KM, Kehrberger JP, Drost A et al, Interferon-gamma inhibits growth of human neuroendocrine carcinoma cells via induction of apoptosis. Int J Oncol (2002) 21: 1133-40.
14. Li JH, Kluger MS, Madge LA et al, Interferon-gamma augments CD95 (APO-1/Fas) and pro-caspase-8 expression and sensitizes human vascular endothelial cells to CD95-mediated apoptosis. Am J Pathol (1996) 161: 1485-95.
15. Coughlin CM, Salhany KE, Gee MS et al, Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 9: 25-34.
16. Yao L, Sgadari C, Furuke K et al, Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood (1999) 93: 1612-21.
17. Terabe M, Matsui S, Noben-Trauth N et al, NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol (2000) 1: 515-20.
18. Kakuta S, Tagawa Y, Shibata S et al, Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology (2002) 105: 92-100.
19. Yim JH, Wu SJ, Lowney JK et al, Enhancing in vivo tumorigenicity of B16 melanoma by overexpressing interferon regulatory factor-2: resistance to endogenous IFN-gamma. J Interferon Cytokine Res (1999) 19: 723-9.
20. Arnould R, Dubois J, Abikhalil F et al, Comparison of two cytotoxicity assays - tetrazolium derivative reduction (MTT) and tritiated thymidine uptake - on three malignant mouse cell lines using chemotherapeutic agents and investigational drugs. Anticancer Res (1990) 10: 145-54.
21. Dias AAM, Goodman AR, Santos JL et al, TSG-14 transgenic mice have improved survival to endotoxemia and to CLP-induced sepsis. J Leuk Biol (2001) 69: 928-36.
22. Taniguchi T, Tanaka N, Taki S, Regulation of the interferon system, immune response and oncogenesis by the transcription factor interferon regulatory factor-1. Eur Cytokine Netw (1998) 9(3 Suppl): 43-8.
23. Romeo G, Fiorucci G, Chiantore MV et al, IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res (2002) 22: 39-47.
24. Huang S, Hendriks W, Althage A et al, Immune response in mice that lack the interferon-gamma receptor. Science (1993) 259: 1742-5.
25. Cui J, Shin T, Kawano T et al, Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science (1997) 278: 1623-6.
26. Garbe C, Krasagakis K, Effects of interferons and cytokines on melanoma cells. J Invest Dermatol (1993) 100(2 Suppl): 239S-44S.
27. Krasagakis K, Garbe C, Zouboulis CC, Orfanos CE, Growth control of melanoma cells and melanocytes by cytokines. Recent Results Cancer Res (1995) 139: 169-82.
28. Harvat BL, Seth P, Jetten AM, The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene (1997) 14: 2111-22.
29. Harvat BL, Jetten AM, Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ (1996) 7: 289-300.
30. Bromberg JF, Horvath CM, Wen Z et al, Transcriptionally active Stat1 is required for the anti-proliferative effects of both interferon-α and intefferon-γ. Proc Nat Acad Sci USA (1996) 93: 7673-8.
31. Mandal M, Bandyopadhyay D, Goepfert TM, Kumar R, Interferon induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene (1998) 16: 217-25.
32. Ikeda H, Old LJ, Schreiber RD, The roles of IFNγ in protection against tumor development and cancer immunoediting. Cytokine Growth Fact Rev (2002) 13: 95-109.
33. Chin YE, Kitagawa M, Kuida K et al, Activation of STAT signaling pathway can cause expression of caspase-1 and apoptosis. Mol Cell Biol (1997) 17: 5328-37.
34. Detjen KM, Farwig K, Welzel M et al, Interferon-γ inhibits growth of human pancreatic carcinoma cells via caspase-1 depedent induction of apoptosis. Gut (2001) 49: 251-62.
35. Xu X, Fu XY, Plate J, Chong AS, IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res (1998) 58: 2832-7.
36. Konan KV, Taylor MW, Treatment of ME180 cells with interferon-gamma causes apoptosis as a result of tryptophan starvation. J Interferon Cytokine Res (1996) 16: 751-6.
37. Ozaki Y, Edelstein MP, Duch DS, Induction of indoleamine 2, 3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Nat Acad Sci USA (1988) 85: 1242-6.
38. Garecitano J, Perle MA, Vilcek J, Transcriptional basis for the differences in inducible nitric oxide synthase (iNOS) expression between nonmetastatic and metastatic murine melanoma cell lines. J Interferon Cytokine Res (1999) 19: 393-405.
39. Dong Z, Staroselsky AH, Qi X et al, Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res (1994) 54: 789-93.
40. Xie K, Dong Z, Fidler IJ, Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol (1996) 59: 797-803.
41. Kaplan DH, Shankaran V, Dighe AS et al, Demonstration of an interferon-γ dependent tumor surveillance system in immunocompetent mice. Proc Nat Acad Sci USA (1998) 95: 7556-61.